We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Intensity Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing an approach to treat solid tumor cancers. It leverages its DfuseRx technology platform to create proprietary drug formulations. Its product candidates have the potential to induce an adaptive... Intensity Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing an approach to treat solid tumor cancers. It leverages its DfuseRx technology platform to create proprietary drug formulations. Its product candidates have the potential to induce an adaptive immune response that attacks the injected and non-injected tumors. The Company's lead product candidate, INT230-6, is in development for the treatment of patients with solid tumors, such as sarcoma and breast cancer patients. The Company, through Merck Sharpe & Dohme (Merck), evaluates INT230-6 with pembrolizumab. In addition, it also evaluates the combination INT230-6 with Bristol-Myers Squibb's anti-CTLA-4 antibody, ipilimumab. It also has an agreement with the Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer (the INVINCIBLE study) (NCT04781725). Show more
Intensity Therapeutics to Participate in the LD Micro Invitational XIV Conference April 8 - 9, 2024 PR Newswire SHELTON, Conn., April 2, 2024 SHELTON, Conn., April 2, 2024 /PRNewswire/...
WESTPORT, Conn., March 26, 2024 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as monotherapy...
Intensity Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update PR Newswire SHELTON, Conn., March 14, 2024 INT230-6, Intensity's lead drug candidate, advances into...
Intensity Therapeutics to Participate in the 36th Annual Roth Conference March 17 to 19, 2024 PR Newswire SHELTON, Conn., March 14, 2024 SHELTON, Conn., March 14, 2024 /PRNewswire/ -- Intensity...
Intensity Therapeutics to Present at the 2024 BIO CEO & Investor Conference PR Newswire SHELTON, Conn., Feb. 21, 2024 SHELTON, Conn., Feb. 21, 2024 /PRNewswire/ -- Intensity Therapeutics...
Intensity Therapeutics Provides Business Update Reflecting Progress in Phase 3 Sarcoma Program PR Newswire SHELTON, Conn., Jan. 3, 2024 FDA provides "Study May Proceed" letter for open-label...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.115 | 3.01837270341 | 3.81 | 4.08 | 3.8 | 5658 | 3.95963522 | CS |
4 | -1.255 | -24.2277992278 | 5.18 | 5.18 | 3.55 | 14183 | 4.40030912 | CS |
12 | -1.065 | -21.3426853707 | 4.99 | 5.94 | 2.6701 | 50010 | 4.22469551 | CS |
26 | 0.725 | 22.65625 | 3.2 | 11.44 | 2.0101 | 332828 | 6.7516259 | CS |
52 | -2.025 | -34.0336134454 | 5.95 | 11.44 | 2.0101 | 216730 | 6.66865102 | CS |
156 | -2.025 | -34.0336134454 | 5.95 | 11.44 | 2.0101 | 216730 | 6.66865102 | CS |
260 | -2.025 | -34.0336134454 | 5.95 | 11.44 | 2.0101 | 216730 | 6.66865102 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions